TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 36
- +4 vs. Q2 2024
- Portfolio value
- $1.18B
- +$220.8M (+23.0%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | COM | 3,670,206 | $138.5M | 11.7% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 2,650,150 | $95.2M | 8.1% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 6,964,375 | $75.2M | 6.4% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 6,056,596 | $69.8M | 5.9% | 00.0% | Unchanged | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 2,112,984 | $56.4M | 4.8% | −159,744−7.0% | Reduced | History |
| SLNSilence Therapeutics plc | ADS | 3,033,560 | $55.2M | 4.7% | −261,790−7.9% | Reduced | History |
| SVRASavara Inc | COM | 12,362,205 | $52.4M | 4.4% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 879,344 | $51.1M | 4.3% | 00.0% | Unchanged | History |
| XNCRXencor Inc | COM | 2,427,138 | $48.8M | 4.1% | +2,427,138 | New | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $46.8M | 4.0% | 00.0% | Unchanged | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 1,063,000 | $46.7M | 4.0% | +368,453+53.0% | Added | History |
| OCULOcular Therapeutix, Inc | COM | 5,319,148 | $46.3M | 3.9% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,890,816 | $46.2M | 3.9% | 00.0% | Unchanged | History |
| TRMLTourmaline Bio, Inc. | COM | 1,477,593 | $38.0M | 3.2% | 00.0% | Unchanged | History |
| THRDThird Harmonic Bio, Inc. | COM | 2,415,000 | $32.7M | 2.8% | +2,415,000 | New | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,761,861 | $30.4M | 2.6% | 00.0% | Unchanged | History |
| MLYSMineralys Therapeutics, Inc. | COM | 2,470,265 | $29.9M | 2.5% | −714,920−22.4% | Reduced | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $27.8M | 2.4% | 00.0% | Unchanged | History |
| SLNOSoleno Therapeutics Inc | COM | 550,000 | $27.8M | 2.4% | +550,000 | New | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 3,858,000 | $24.3M | 2.1% | 00.0% | Unchanged | History |
| IRONDisc Medicine, Inc. | COM | 486,957 | $23.9M | 2.0% | 00.0% | Unchanged | History |
| FULCFulcrum Therapeutics, Inc. | COM | 5,250,000 | $18.7M | 1.6% | +5,250,000 | New | History |
| MBXMBX Biosciences, Inc. | COM | 650,000 | $16.9M | 1.4% | +650,000 | New | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 4,643,812 | $15.0M | 1.3% | +4,643,812 | New | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 2,008,339 | $14.1M | 1.2% | +2,008,339 | New | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $9.35M | 0.8% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM | 2,676,580 | $8.06M | 0.7% | +2,676,580 | New | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 231,820 | $7.62M | 0.6% | −324,497−58.3% | Reduced | History |
| EYPTEyePoint, Inc. | COM NEW | 922,335 | $7.37M | 0.6% | 00.0% | Unchanged | History |
| NKTRNektar Therapeutics | COM | 4,000,000 | $5.20M | 0.4% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 2,240,809 | $4.68M | 0.4% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 483,000 | $4.59M | 0.4% | +483,000 | New | History |
| KODKodiak Sciences Inc. | COM | 1,008,158 | $2.63M | 0.2% | +108,159+12.0% | Added | History |
| ANTXAN2 Therapeutics, Inc. | COM | 1,555,118 | $1.66M | 0.1% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 316,195 | $689.3K | 0.1% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 86,795 | $409.7K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q2 2024 (5)
Positions held at the end of Q2 2024 that are gone from this filing.
| Security | Class | Shares in Q2 2024 | Value in Q2 2024 | % of portfolio in Q2 2024 | History |
|---|---|---|---|---|---|
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 149,283 | $41.8M | 4.4% | History |
| SLNOSoleno Therapeutics Inc | COM NEW | 550,000 | $22.4M | 2.3% | History |
| ADVMAdverum Biotechnologies, Inc. | COM | 2,008,340 | $13.8M | 1.4% | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 2,676,580 | $9.31M | 1.0% | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 1,276,574 | $5.90M | 0.6% | History |